AMENDMENT NO. 1 TO MASTER AGREEMENT FOR JOINT DEVELOPMENT VEHICLEMaster Agreement • March 15th, 2013 • Unigene Laboratories Inc • Medicinal chemicals & botanical products
THIS AMENDMENT NO. 1 (this “Amendment”) is entered into as of the 15th day of August, 2012 (the “Amendment No. 1 Effective Date”) by and between Unigene Laboratories, Inc., a Delaware corporation (“Unigene”) and Nordic Bioscience Clinical Development A/S, a Danish limited liability company (“Nordic”), and amends that certain Master Agreement for Joint Development Vehicle between Unigene and Nordic dated October 5, 2011 (the “Original Agreement” and collectively with this Amendment, the “Agreement”). For good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, the parties agree as follows:
SETTLEMENT AGREEMENTSettlement Agreement • March 15th, 2013 • Unigene Laboratories Inc • Medicinal chemicals & botanical products • New York
THIS SETTLEMENT AGREEMENT (the “Settlement Agreement”) is made as of the 21st day of December, 2012 between Ostrolenk Faber LLP (“Ostrolenk”), on the one hand, and Unigene Laboratories, Inc. and Unigene Patent Properties Nos. 1 through 120 (collectively, (“Unigene”), on the other hand. Intending to be legally bound, the parties hereto hereby stipulate and agree as follows:
